Company Filing History:
Years Active: 2017
**Title: Innovations by Inventor Stephan M Patrick in DNA Repair Mechanisms**
Introduction
Stephan M Patrick, based in Toledo, Ohio, has made significant contributions to the field of biotechnology. With a focus on enhancing cancer treatment efficacy, his work addresses critical challenges in fighting drug resistance in cancer therapies.
Latest Patents
Patrick holds a patent titled "Inhibitors of ERCC1-XPF and methods of using the same." This invention revolves around compositions and methodologies for inhibiting the DNA repair protein complex, ERCC1-XPF. The patent outlines methods to augment clinical responses to anticancer drugs, such as cisplatin, while simultaneously tackling drug resistance resulting from DNA repair mechanisms.
Career Highlights
Currently, Stephan M Patrick is affiliated with the University of Toledo, where he engages in advanced research on genetic therapies and cancer treatment. His innovative efforts have paved the way for more effective treatments, impacting patient care significantly.
Collaborations
Throughout his career, Patrick has collaborated with esteemed colleagues, including Paul W Erhardt and Christopher J Trabbic. These partnerships highlight the collaborative spirit of scientific research and the importance of teamwork in the pursuit of groundbreaking innovations.
Conclusion
Stephan M Patrick's contributions to the scientific community, particularly through his patented work, exemplify the critical intersection of innovation and healthcare. His research stands to not only enhance cancer treatment options but also improve outcomes for many patients battling this challenging disease.